HSTO - Histogen Inc. Stock Price and Quote

HSTO [NASD]

Index	-	P/E	-	EPS (ttm)	-3.52	Insider Own	2.87%	Shs Outstand	4.28M	Perf Week	54.52%
Market Cap	3.92M	Forward P/E	-	EPS next Y	-3.73	Insider Trans	0.00%	Shs Float	4.15M	Perf Month	34.09%
Income	-11.10M	PEG	-	EPS next Q	-1.11	Inst Own	3.00%	Short Float / Ratio	0.24% / 0.01	Perf Quarter	49.08%
Sales	3.80M	P/S	1.03	EPS this Y	55.60%	Inst Trans	53.31%	Short Interest	0.01M	Perf Half Y	-19.43%
Book/sh	3.36	P/B	0.42	EPS next Y	-0.80%	ROA	-47.40%	Target Price	2.00	Perf Year	-73.70%
Cash/sh	4.35	P/C	0.32	EPS next 5Y	38.00%	ROE	-64.70%	52W Range	0.76 - 9.40	Perf YTD	69.88%
Dividend	-	P/FCF	-	EPS past 5Y	50.90%	ROI	-73.90%	52W High	-85.00%	Beta	1.35
Dividend %	-	Quick Ratio	-	Sales past 5Y	-36.10%	Gross Margin	-	52W Low	85.45%	ATR	0.16
Employees	7	Current Ratio	10.90	Sales Q/Q	-20.00%	Oper. Margin	-	RSI (14)	72.64	Volatility	23.00% 12.54%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	52.70%	Profit Margin	-	Rel Volume	2.10	Prev Close	1.41
Shortable	No	LT Debt/Eq	0.00	Earnings	Mar 09 AMC	Payout	-	Avg Volume	985.07K	Price	1.41
Recom	1.00	SMA20	38.89%	SMA50	35.67%	SMA200	-10.76%	Volume	344,944	Change	0.00%

Mar-16-23 04:05PM	Histogen Announces Issuance of US Patent Covering CTS-2090 Methods of Use GlobeNewswire
Mar-09-23 04:05PM	Histogen Reports Year-End 2022 Results and Provides Business Update GlobeNewswire -11.96%
Feb-27-23 04:15PM	Histogen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jan-03-23 04:05PM	Histogen Hires Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer GlobeNewswire
Nov-10-22 04:15PM	Histogen Reports Third Quarter 2022 Financial Results and Provides Business Update GlobeNewswire -5.45%
04:05PM	Loading…
Aug-11-22 04:05PM	Histogen Reports Second Quarter 2022 Financial Results and Provides Business Update GlobeNewswire -5.36%
Jul-27-22 04:05PM	Histogen to Report Second Quarter 2022 Financial Results and Provide Business Update GlobeNewswire
Jul-14-22 04:05PM	Histogen Announces Closing of $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules GlobeNewswire -17.47%
Jul-12-22 11:40AM	Histogen Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules GlobeNewswire +27.46%
Jun-01-22 04:00PM	Histogen Announces 1-for-20 Reverse Stock Split GlobeNewswire -6.44%
May-17-22 04:05PM	Histogen to Present at the H.C. Wainwright Global Investment Conference GlobeNewswire +21.34%
May-12-22 04:05PM	Histogen Reports First Quarter 2022 Financial Results and Provides Business Update GlobeNewswire +5.80%
Apr-28-22 04:05PM	Histogen to Report First Quarter 2022 Financial Results and Provide Business Update GlobeNewswire
Mar-25-22 04:05PM	Histogen Announces Closing of $4.75 Million Private Placement GlobeNewswire
Mar-23-22 08:00AM	Histogen Announces $4.75 Million Private Placement GlobeNewswire +7.17%
04:05PM	Loading…
Mar-10-22 04:05PM	Histogen Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update GlobeNewswire
Mar-03-22 04:15PM	Histogen to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Business Update GlobeNewswire
Dec-21-21 06:19PM	Histogen Announces Closing of $3.5 Million Private Placement GlobeNewswire
Dec-16-21 08:00AM	Histogen Announces $3.5 Million Private Placement GlobeNewswire -10.56%
Nov-26-21 05:11AM	Histogen (NASDAQ:HSTO) Will Have To Spend Its Cash Wisely Simply Wall St.
Nov-10-21 04:05PM	Histogen Reports Third Quarter 2021 Earnings and Provides Business Update GlobeNewswire -8.48%
Nov-08-21 04:05PM	Histogen Announces CEO Transition GlobeNewswire
Nov-02-21 08:00AM	Histogen and Amerimmune Announce the Presentation of Emricasan Data in COVID-19 at the American College of Allergy, Asthma, and Immunology Conference GlobeNewswire
Oct-27-21 08:00AM	Histogen to Report Third Quarter 2021 Financial Results on November 10, 2021 GlobeNewswire
Aug-31-21 04:05PM	Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire
Aug-16-21 08:00AM	Histogen and Amerimmune Announce Additional Findings from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients GlobeNewswire -5.03%
Aug-11-21 04:05PM	Histogen Reports Second Quarter 2021 Earnings and Provides Business Update GlobeNewswire +6.16%
Jul-29-21 04:05PM	Histogen to Present at the Canaccord Genuity 41st Annual Growth Conference GlobeNewswire
Jul-28-21 04:05PM	Histogen to Report Second Quarter 2021 Financial Results on August 11, 2021 GlobeNewswire
Jun-30-21 08:00AM	Histogen Announces Initiation of HST 003 Phase 1/2 Trial for Knee Cartilage Regeneration GlobeNewswire
08:00AM	Loading…
Jun-22-21 08:00AM	Histogen and Amerimmune Announce Positive Top-Line Study Results from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients GlobeNewswire +16.16%
Jun-09-21 04:01PM	Histogen Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules GlobeNewswire
Jun-07-21 04:05PM	Histogen Announces $6.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules GlobeNewswire +6.93%
Jun-03-21 08:00AM	Histogen Provides Update on its Development Programs and Pipeline Focus GlobeNewswire -5.15%
May-19-21 08:00AM	Histogen and Amerimmune Report Publication on Emricasan in COVID-19 GlobeNewswire
May-13-21 04:01PM	Histogen Reports First Quarter 2021 Earnings and Provides Business Update GlobeNewswire -5.94%
Apr-28-21 04:05PM	Histogen to Report Second Quarter 2021 Financial Results and Provide Business Update GlobeNewswire +9.62%
Mar-30-21 08:00AM	Histogen to Present at the 20th Annual Needham Virtual Healthcare Conference GlobeNewswire
Mar-25-21 04:05PM	Histogen Appoints Rochelle Fuhrmann to Board of Directors GlobeNewswire
Mar-16-21 08:00AM	Histogen and Amerimmune Announce First Patient Dosed in Phase 1 Study of Emricasan in Symptomatic COVID-19 Patients GlobeNewswire
Mar-15-21 08:00AM	Histogen Announces Removal of Clinical Hold by FDA for HST-003 IND to Initiate a Phase 1/2 Trial for Knee Cartilage Regeneration GlobeNewswire +6.67%
Mar-11-21 04:01PM	Histogen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Update GlobeNewswire +15.45%
Mar-10-21 04:05PM	Histogen Strengthens Board of Directors with Appointment of Industry Leader Susan Windham-Bannister, Ph.D. GlobeNewswire
Mar-04-21 04:05PM	Histogen to Report Fourth Quarter and Year-End 2020 Financial Results and Provide Business Update GlobeNewswire
Mar-02-21 08:00AM	Histogen to Present at the H.C. Wainwright Global Life Sciences Virtual Conference GlobeNewswire
Feb-16-21 08:00AM	Histogen Announces Week 26 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men GlobeNewswire
Jan-19-21 04:05PM	Histogen Reports FDA Clinical Hold for Planned Phase 1/2 Trial of HST-003 for Knee Cartilage Regeneration GlobeNewswire +15.69%
Jan-07-21 09:46AM	DLA Piper advises Histogen in its US$14 million upsized public offering PR Newswire
Jan-06-21 08:00AM	Histogen to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference GlobeNewswire
Jan-05-21 04:05PM	Histogen Announces Closing of $14.0 Million Upsized Public Offering GlobeNewswire +7.04%
Dec-30-20 10:25PM	Histogen Announces Pricing of $14.0 Million Upsized Public Offering GlobeNewswire
Dec-17-20 08:00AM	Histogen Announces Filing an Investigational New Drug Application for HST-003 GlobeNewswire
Dec-01-20 08:00AM	Histogen Announces Preliminary Week 18 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men GlobeNewswire -17.61%
Nov-16-20 04:05PM	Histogen Announces Closing of $4.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules GlobeNewswire
Nov-12-20 08:00AM	Histogen Announces $4.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules GlobeNewswire -12.50%
Nov-10-20 04:05PM	Histogen Reports Third Quarter 2020 Earnings and Provides Business Update GlobeNewswire
Oct-28-20 04:30PM	Histogen to Report Third Quarter 2020 Earnings on November 12, 2020 GlobeNewswire
Oct-27-20 08:00AM	Histogen and Amerimmune Enter into a Collaborative Development and Commercialization Agreement for Emricasan in the Treatment of COVID-19 GlobeNewswire -7.14%
Oct-19-20 08:00AM	Histogen Appoints Moya Daniels as Executive Vice President and Head of Regulatory, Quality and Clinical Operations GlobeNewswire
Oct-05-20 08:00AM	Histogen Announces Completion of Final Dosing Timepoint Milestone in its 1b/2a Trial for Androgenic Alopecia in Men GlobeNewswire +12.10%
Sep-29-20 08:00AM	Histogen Announces Update for its HST-002 Dermal Filler Program GlobeNewswire
Sep-16-20 08:00AM	Histogen Announces $2M Grant Award from the Department of Defense for Clinical Advancement of HST-003 for Cartilage Regeneration in the Knee GlobeNewswire
Sep-10-20 08:00AM	Histogen Announces Completion of Dosing Milestone in its 1b/2a Trial for Androgenic Alopecia in Men GlobeNewswire
Sep-01-20 04:15PM	Histogen to Present at the HC Wainwright 22nd Annual Global Investment Conference GlobeNewswire
Aug-13-20 04:05PM	Histogen Reports Second Quarter 2020 Earnings and Provides Business Update GlobeNewswire
Jul-30-20 04:15PM	Histogen to Report Second Quarter 2020 Earnings on August 13, 2020 GlobeNewswire
Jul-29-20 04:15PM	Histogen to Present at the Canaccord Genuity 40th Annual Growth Conference GlobeNewswire
Jul-20-20 04:10PM	Histogen Inc. Announces Common Stock Purchase Agreement for up to $10 Million with Lincoln Park Capital Fund, LLC GlobeNewswire
Jul-14-20 05:00AM	Histogen Announces Completion of Patient Enrollment for its HST 001 Phase 1b/2a Trial for Androgenic Alopecia in Men GlobeNewswire
Jun-03-20 08:00AM	Histogen to Present at BIO Digital 2020 GlobeNewswire +5.77%

Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience